POSSIBILITIES OF EFFECTIVE INTERACTION IN THE PHARMACOVIGILANCE SYSTEM AT REGISTERING UNDESIRABLE MEDICINAL REACTIONS IN SENIOR PATIENTS

In the recent years, complications of drug therapy are an important medical problem. Data on adverse drug reactions (ADRs) in older patients were analyzed. The object of the study was notification cards for NR received from medical organizations (MO) of Irkutsk region for a five-year period. The Narangio scale was used to assess the causality (SST) between ADR and LS. Of the 1068 ADR notifications in patients over 60 years of age, 2/3 (705) are presented with ADR notifications in women, 363 (34.0 %) – in men. The presence of background diseases was registered in 940 notifications (88.0 %). There were no gender differences except for a higher incidence of chronic obstructive pulmonary disease in men (7.2 % and 3.5 %, respectively, p < 0.05) and diabetes mellitus in women (14.0 % and 3.5 %, respectively, p < 0.05). ARs for antibacterial agents amounted to 31.8 %, drugs for the treatment of cardiovascular diseases – 10.5 %, cases of therapeutic inefficiency – 5.4 %. The ADR data statement was in line with the recommended form of 76 %. The most common filling defect was incomplete patient information. The validity of the Narango PSS was high. The deadlines for reporting data were observed in 93 %. For effective interaction in the pharmacovigilance system, it is necessary for each MO to constantly inform about the procedure for pharmacovigilance, types of ADRs, the rules for their detection and the timing of data reporting. The work should be supervised by a trained specialist.

1. Alieva AA, Nikitin IG, Arkhipov AV. Concomitant therapy of acute drug-induced liver injury during chemotherapeutic treatment in patients with breast cancer. General Medicine. 2018;2:74–84. (in Russian)

2. Vasyuk YuA, Shupenina EY, Novosel EO, Agapov IS. Heart rhythm and conduction disturbances as manifestations of cardiotoxicity of antitumor treatment – myth or reality? Siberian Journal of Clinical and Experimental Medicine. 2020;Vol. 35:1:13–21. (in Russian)

3. Glagolev SV, Gorelov KV, Chizhova DA. Development of the pharmacovigilance system in the Russian Federation. Bulletin of Roszdravnadzor. 2019;2:72–77. (in Russian)

4. GOST R ISO 9001-2015 Quality management systems. Requirements.

5. GOST R ISO 9000-2015 Quality management systems. Basic provisions and vocabulary.

6. Demchenkova EYu, Gorodetskaya GI, Mazerkina IA, et al. Actual issues of detection and monitoring of adverse reactions during the use of cephalosporin antibiotics. Safety and Risk of Pharmacotherapy. 2021;Vol.9,1:34–42. (in Russian)

7. Kazakov AS. Determination of the degree of reliability of the causal relationship “adverse reaction – drug interaction”. Russian Medical Journal. 2013;5:38–43. (in Russian)

8. Krupnova IV, Starostina IS. Current issues of prevention of violations in the field of circulation of medicines. Bulletin of Roszdravnadzor. 2019;2:40–49. (in Russian)

9. Kudryavtseva EM, Gorelov KV. Conducting pharmacovigilance in medical organizations. Bulletin of Roszdravnadzor. 2021;2:53–57. (in Russian)

10. Makhmutova NM, Zheterova SK. Modern aspects of the implementation of the pharmacovigilance system. Avicenna. 2018;8–12. (in Russian)

11. Murashko MA Roszdravnadzor today. Bulletin of Roszdravnadzor. 2019;2:9–20. (in Russian)

12. Byeon JH, Kil JH, Ahn YC, Son CG. Systematic review of published data on herb induced liver injury. J Ethnopharmacol. 2019; 233:190–6. https://doi.org/10.1016/j.jep.2019.01.006

13. Comfort S, Dorrell D, Meireis S, Fine J. Modified NARanjo causality scale for ICSRs (MONARCSI): A decision support tool for safety scientists. Drug Saf. 2018;11(41):1073 85. https://doi.org/10.1007/s40264-018-0690-y

14. Mody H, Ramakrishnan V, Chaar M, et al. A review on drug-induced nephrotoxicity: pathophysiological mechanisms, drug classes, clinical management, and recent advances in mathematical modeling and simulation approaches. Clin Pharmacol Drug Dev. 2020;9(8):896–909. https://doi.org/10.1002/cpdd.879

15. Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. 2019;156(8):2230–41.e11. https://doi.org/10.1053/j.gastro.2019.02.002

16. Wu H, Huang J. Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies. Curr Drug Metab. 2018;19(7):559–67. https://doi.org/10.2174/1389200218666171108154419

17. Zamoner W, Prado IRS, Balbi AL, Ponce D. Vancomycin dosing, monitoring and toxicity: critical review of the clinical practice. Clin Exp Pharmacol Physiol. 2019;46(4):292–301. https://doi.org/10.1111/1440-1681.13066